Skip to main content
SpringerLink
Log in

Primary Testicular Lymphoma

  • Chapter
  • First Online:
Radiation Therapy in Hematologic Malignancies

  • 874 Accesses

Abstract

Adjuvant testicular irradiation is a component of standard care for patients with stage I–II primary testicular lymphomas following anthracycline-based chemotherapy and improves both local disease control and overall outcome in appropriately selected patients. It can also be considered in advanced stage III/IV patients on a case-by-case basis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moller MB, d’Amore F, Christensen BE. Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. The Danish Lymphoma Study Group, LYFO. Eur J Cancer. 1994;30A(12):1760–4.

    Article  CAS  PubMed  Google Scholar 

  2. Gundrum JD, et al. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009;27(31):5227–32.

    Article  PubMed  Google Scholar 

  3. Shahab N, Doll DC. Testicular lymphoma. Semin Oncol. 1999;26(3):259–69.

    CAS  PubMed  Google Scholar 

  4. Fonseca R, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000;88(1):154–61.

    Article  CAS  PubMed  Google Scholar 

  5. Hasselblom S, et al. Testicular lymphoma--a retrospective, population-based, clinical and immunohistochemical study. Acta Oncol. 2004;43(8):758–65.

    Article  PubMed  Google Scholar 

  6. Seymour JF, et al. Primary large-cell non-Hodgkin’s lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma. 2001;2(2):109–15.

    Article  CAS  PubMed  Google Scholar 

  7. Vitolo U, Ferreri AJ, Zucca E. Primary testicular lymphoma. Crit Rev Oncol Hematol. 2008;65(2):183–9.

    Article  PubMed  Google Scholar 

  8. Horne MJ, Adeniran AJ. Primary diffuse large B-cell lymphoma of the testis. Arch Pathol Lab Med. 2011;135(10):1363–7.

    Article  PubMed  Google Scholar 

  9. Crellin AM, et al. Non-Hodgkin’s lymphoma of the testis. Radiother Oncol. 1993;27(2):99–106.

    Article  CAS  PubMed  Google Scholar 

  10. Aviles A, et al. Testicular lymphoma: organ-specific treatment did not improve outcome. Oncology. 2004;67(3–4):211–4.

    Article  CAS  PubMed  Google Scholar 

  11. Mazloom A, et al. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma. 2010;51(7):1217–24.

    Article  CAS  PubMed  Google Scholar 

  12. Zucca E, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20–7.

    Article  CAS  PubMed  Google Scholar 

  13. Verma N, et al. Primary testicular lymphoma and AIDS. Ann Clin Lab Sci. 2010;40(1):75–9.

    PubMed  Google Scholar 

  14. Barta SK, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Booman M, et al. Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics. J Pathol. 2006;210(2):163–71.

    Article  CAS  PubMed  Google Scholar 

  16. Li D, Xie P, Mi C. Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype. Pathol Res Pract. 2010;206(9):611–5.

    Article  CAS  PubMed  Google Scholar 

  17. Al-Abbadi MA, et al. Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: a study of 18 cases. Mod Pathol. 2006;19(12):1521–7.

    Article  CAS  PubMed  Google Scholar 

  18. Kemmerling R, et al. Primary testicular lymphoma: a strictly homogeneous hematological disease? Oncol Rep. 2010;23(5):1261–7.

    PubMed  Google Scholar 

  19. Hans CP, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.

    Article  CAS  PubMed  Google Scholar 

  20. Colomo L, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101(1):78–84.

    Article  CAS  PubMed  Google Scholar 

  21. Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.

    Article  CAS  PubMed  Google Scholar 

  22. Davis RE, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Hu S, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021–31; quiz 4250.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bernasconi B, et al. Gene translocations in testicular lymphomas. Leuk Lymphoma. 2014;55:1410–2.

    Article  PubMed  Google Scholar 

  25. Menter T, et al. Phenotype profiling of primary testicular diffuse large B-cell lymphomas. Hematol Oncol. 2014;32(2):72–81.

    Article  CAS  PubMed  Google Scholar 

  26. Ngo VN, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–9.

    Article  CAS  PubMed  Google Scholar 

  27. Kraan W, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013;3:e139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Epstein AS, et al. Testis-isolated mantle cell lymphoma: a unique case. Clin Lymphoma Myeloma Leuk. 2011;11(5):439–41.

    Article  PubMed  Google Scholar 

  29. Licci S, Morelli L, Covello R. Primary mantle cell lymphoma of the testis. Ann Hematol. 2011;90(4):483–4.

    Article  PubMed  Google Scholar 

  30. Liang DN, et al. Extranodal nasal type natural killer/T-cell lymphoma of testis: report of seven cases with review of literature. Leuk Lymphoma. 2012;53(6):1117–23.

    Article  CAS  PubMed  Google Scholar 

  31. Jun HJ, et al. Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma. Cancer Res Treat. 2007;39(1):40–3.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kuper-Hommel MJ, et al. Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. Leuk Lymphoma. 2012;53(2):242–6.

    Article  PubMed  Google Scholar 

  33. Lagmay J, et al. Primary testicular presentation of ALK-1-negative anaplastic large cell lymphoma in a pediatric patient. J Pediatr Hematol Oncol. 2009;31(5):330–2.

    Article  PubMed  Google Scholar 

  34. Bacon CM, et al. Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol. 2007;31(7):1050–8.

    Article  PubMed  Google Scholar 

  35. Finn LS, et al. Primary follicular lymphoma of the testis in childhood. Cancer. 1999;85(7):1626–35.

    Article  CAS  PubMed  Google Scholar 

  36. Pakzad K, et al. Follicular large cell lymphoma localized to the testis in children. J Urol. 2002;168(1):225–8.

    Article  PubMed  Google Scholar 

  37. Pileri SA, et al. Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics. J Clin Pathol. 2002;55(9):684–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Liu Q, et al. Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol. 2013;37(3):333–43.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Heller KN, et al. Primary follicular lymphoma of the testis: excellent outcome following surgical resection without adjuvant chemotherapy. J Pediatr Hematol Oncol. 2004;26(2):104–7.

    Article  PubMed  Google Scholar 

  40. Dunn GP, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–8.

    Article  CAS  PubMed  Google Scholar 

  41. Thompsett AR, et al. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood. 1999;94(5):1738–46.

    CAS  PubMed  Google Scholar 

  42. Booman M, et al. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. Clin Cancer Res. 2006;12(9):2698–705.

    Article  CAS  PubMed  Google Scholar 

  43. Riemersma SA, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood. 2000;96(10):​3569–77.

    CAS  PubMed  Google Scholar 

  44. Bart J, et al. An oncological view on the blood-testis barrier. Lancet Oncol. 2002;3(6):357–63.

    Article  PubMed  Google Scholar 

  45. Mital P, Hinton BT, Dufour JM. The blood-testis and blood-epididymis barriers are more than just their tight junctions. Biol Reprod. 2011;84(5):851–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Fijak M, Bhushan S, Meinhardt A. Immunoprivileged sites: the testis. Methods Mol Biol. 2011;677:459–70.

    Article  CAS  PubMed  Google Scholar 

  47. Domanska UM, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49(1):219–30.

    Article  CAS  PubMed  Google Scholar 

  48. Chapuy B, et al. Actionable genetic features of primary testicular and primary central nervous system lymphomas in ASH Annual Meeting Abstracts. 2014.

    Google Scholar 

  49. Moorjani V, et al. Sonographic appearance of primary testicular lymphoma. AJR Am J Roentgenol. 1991;157(6):1225–6.

    Article  CAS  PubMed  Google Scholar 

  50. Srisuwan T, et al. Clinics in diagnostic imaging (134). Testicular lymphoma. Singapore Med J. 2011;52(3):204–8.

    CAS  PubMed  Google Scholar 

  51. Tsili AC, et al. Primary diffuse large B-cell testicular lymphoma: magnetic resonance imaging findings. Andrologia. 2012;44 Suppl 1:845–7.

    Article  PubMed  Google Scholar 

  52. Ponti G, et al. The impact of histopathologic diagnosis on the proper management of testis neoplasms. Nat Clin Pract Oncol. 2008;5(10):619–22.

    Article  PubMed  Google Scholar 

  53. Benevolo G, et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood. 2012;120(16):3222–8.

    Article  CAS  PubMed  Google Scholar 

  54. Muniesa C, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type and secondary cutaneous involvement by testicular B-cell lymphoma share identical clinicopathological and immunophenotypical features. J Am Acad Dermatol. 2012;66(4):650–4.

    Article  PubMed  Google Scholar 

  55. Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas. Cancer Treat Rep. 1977;61(6):1023–7.

    CAS  PubMed  Google Scholar 

  56. Lagrange JL, et al. Non-Hodgkin’s lymphoma of the testis: a retrospective study of 84 patients treated in the French anticancer centres. Ann Oncol. 2001;12(9):1313–9.

    Article  CAS  PubMed  Google Scholar 

  57. Go RS, Gundrum JD. Uncertainty and discordance in the staging and prognosis of diffuse large B-cell lymphoma with isolated bilateral testicular involvement. Am J Hematol. 2009;84(11):762–3.

    Article  PubMed  Google Scholar 

  58. Wittekind C, et al. UICC-TNM Supplement. A commentary on uniform use (second edition). 2nd ed. New York: Wiley-Liss Publishers; 2001.

    Google Scholar 

  59. Vitolo U, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29(20):2766–72.

    Article  CAS  PubMed  Google Scholar 

  60. Wang Y, et al. Three prognostic factors influence clinical outcomes of primary testicular lymphoma. Tumour Biol. 2013;34(1):55–63.

    Article  PubMed  CAS  Google Scholar 

  61. Cao B, et al. A clinical analysis of primary testicular diffuse large B-cell lymphoma in China. Hematology. 2011;16(5):291–7.

    Article  PubMed  Google Scholar 

  62. Ferry JA, et al. Malignant lymphoma of the testis, epididymis, and spermatic cord. A clinicopathologic study of 69 cases with immunophenotypic analysis. Am J Surg Pathol. 1994;18(4):376–90.

    Article  CAS  PubMed  Google Scholar 

  63. Park B-B, et al. Consideration of aggressive therapeutic strategies for primary testicular lymphoma. Am J Hematol. 2007;82(9):840–5.

    Article  PubMed  Google Scholar 

  64. Telio D, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. ASH Annu Meet Abstr. 2011;118(21):780.

    Google Scholar 

  65. Touroutoglou N, et al. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. J Clin Oncol. 1995;13(6):1361–7.

    CAS  PubMed  Google Scholar 

  66. Buskirk SJ, et al. Primary lymphoma of the testis. Int J Radiat Oncol Biol Phys. 1982;8(10):1699–703.

    Article  CAS  PubMed  Google Scholar 

  67. Tondini C, et al. Diffuse large-cell lymphoma of the testis. J Clin Oncol. 1999;17(9):2854–8.

    CAS  PubMed  Google Scholar 

  68. Connors JM, et al. Testicular lymphoma: improved outcome with early brief chemotherapy. J Clin Oncol. 1988;6(5):776–81.

    CAS  PubMed  Google Scholar 

  69. Linassier C, et al. Stage I-IIE primary non-Hodgkin’s lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group. Clin Lymphoma. 2002;3(3):167–72.

    Article  PubMed  Google Scholar 

  70. Aviles A, et al. Rituximab and dose-dense chemotherapy in primary testicular lymphoma. Clin Lymphoma Myeloma. 2009;9(5):386–9.

    Article  CAS  PubMed  Google Scholar 

  71. Zhang LH, et al. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160(4):487–502.

    Article  CAS  PubMed  Google Scholar 

  72. Wilson WH, et al. The Bruton’s Tyrosine Kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. ASH Annu Meet Abstr. 2012;120(21):686.

    Google Scholar 

  73. Nowakowski GS, et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011;25(12):1877–81.

    Article  CAS  PubMed  Google Scholar 

  74. Chiappella A, et al. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated elderly diffuse large B-cell lymphoma patients: phase I study by the Fondazione Italiana Linfomi. Haematologica. 2013;98(11):1732–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Tilly H, et al. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia. 2013;27(1):252–5.

    Article  CAS  PubMed  Google Scholar 

  76. Wang M, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27:1902–9.

    Article  CAS  PubMed  Google Scholar 

  77. Chen N, et al. Distribution of lenalidomide into semen of healthy men after multiple oral doses. J Clin Pharmacol. 2010;50(7):767–74.

    Article  CAS  PubMed  Google Scholar 

  78. Miyao K, et al. Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report. Ann Hematol. 2014;93(3):529–30.

    Article  PubMed  Google Scholar 

  79. Hernandez-Ilizaliturri FJ, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005;11(16):5984–92.

    Article  CAS  PubMed  Google Scholar 

  80. Li Z, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013;8(8):e71754.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Lam LT, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111(7):3701–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Lote K, Holte H, Kvaloy S. Testicular lymphoma is associated with a high risk of extranodal recurrence. Cancer. 2000;89(3):713–4.

    Article  CAS  PubMed  Google Scholar 

  83. Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2013;0(ja):1–16.

    Google Scholar 

  84. Rubenstein JL, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25(11):1350–6.

    Article  CAS  PubMed  Google Scholar 

  85. Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? Blood Rev. 2012;26(3):97–106.

    Article  PubMed  Google Scholar 

  86. Balis FM, et al. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol. 2000;45(3):259–64.

    Article  CAS  PubMed  Google Scholar 

  87. Zylber-Katz E, et al. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood–brain barrier disruption in patients with brain lymphoma. Clin Pharmacol Ther. 2000;67(6):631–41.

    Article  CAS  PubMed  Google Scholar 

  88. Tilly H, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102(13):4284–9.

    Article  CAS  PubMed  Google Scholar 

  89. Holte H, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013;24(5):1385–92.

    Article  CAS  PubMed  Google Scholar 

  90. Abramson JS, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116(18):4283–90.

    Article  PubMed  Google Scholar 

  91. Cheah CY, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111(6):1072–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. McMillan A, et al. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. Br J Haematol. 2013;163(2):168–81.

    PubMed  Google Scholar 

  93. Greene-Schloesser D, et al. Radiation-induced brain injury: a review. Front Oncol. 2012;2:73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Sussman EB, et al. Malignant lymphoma of the testis: a clinicopathologic study of 37 cases. J Urol. 1977;118(6):1004–7.

    CAS  PubMed  Google Scholar 

  95. Connors JM. Problems in lymphoma management: special sites of presentation. Oncology (Williston Park). 1998;12(2):185–91; discussion 192–5.

    CAS  Google Scholar 

  96. Brouwer CL, et al. Scrotal irradiation in primary testicular lymphoma: review of the literature and in silico planning comparative study. Int J Radiat Oncol Biol Phys. 2013;85(2):298–308.

    Article  PubMed  Google Scholar 

  97. Conrad AL, Go RS. Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma. Eur J Haematol. 2009;83(6):603–5.

    Article  PubMed  Google Scholar 

  98. Visco C, et al. Non-Hodgkin’s lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clin Lymphoma. 2001;2(1):40–6.

    Article  CAS  PubMed  Google Scholar 

  99. Zietman AL, et al. The management and outcome of stage IAE non Hodgkin’s lymphoma of the testis. J Urol. 1996;155(3):943–6.

    Article  CAS  PubMed  Google Scholar 

  100. Wirth A. The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era. Leuk Lymphoma. 2007;48(11):2121–36.

    Article  CAS  PubMed  Google Scholar 

  101. Phan J, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28(27):4170–6.

    Article  PubMed  Google Scholar 

  102. Martelli M, et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146–71.

    Article  PubMed  Google Scholar 

  103. Held G, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32(11):1112–8.

    Article  PubMed  Google Scholar 

  104. Illidge T, Specht L, Yahalom J, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2014;89(1):49–58.

    Article  PubMed  Google Scholar 

  105. Hoskin PJ, et al. Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol). 2013;25(1):49–58.

    Article  CAS  Google Scholar 

  106. Shapiro E, et al. Effects of fractionated irradiation of endocrine aspects of testicular function. J Clin Oncol. 1985;3(9):1232–9.

    CAS  PubMed  Google Scholar 

  107. Lowry L, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92.

    Article  PubMed  Google Scholar 

  108. Shalet SM, et al. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. J Endocrinol. 1989;120(1):161–5.

    Article  CAS  PubMed  Google Scholar 

  109. Petersen PM, et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol. 2002;20(6):1537–43.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Radiation Oncology and Cancer Imaging, Peter MacCallum cancer Centre, East Melbourne, VIC, Australia

    Andrew Wirth

  2. Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA

    Chan Yoon Cheah

Authors
  1. Andrew Wirth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chan Yoon Cheah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Wirth .

Editor information

Editors and Affiliations

  1. University of Texas, MD Anderson Cancer Center, Houston, Texas, USA

    Bouthaina Shbib Dabaja

  2. Dana-Farber Cancer Institute, Harvard University Medical School, Boston, Massachusetts, USA

    Andrea K. Ng

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Wirth, A., Cheah, C.Y. (2017). Primary Testicular Lymphoma. In: Dabaja, B., Ng, A. (eds) Radiation Therapy in Hematologic Malignancies . Springer, Cham. https://doi.org/10.1007/978-3-319-42615-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42615-0_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42613-6

  • Online ISBN: 978-3-319-42615-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation